Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
349 Leser
Artikel bewerten:
(2)

Tortoise Capital Announces Closed-End Fund Distributions

Finanznachrichten News

Distribution Amounts and Dates Declared for:

  • Tortoise Energy Infrastructure Corp. (NYSE:TYG)

  • Tortoise Midstream Energy Fund, Inc. (NYSE:NTG)

  • Tortoise Pipeline & Energy Fund, Inc. (NYSE:TTP)

  • Tortoise Energy Independence Fund, Inc. (NYSE:NDP)

  • Tortoise Power and Energy Infrastructure Fund, Inc. (NYSE:TPZ)

  • Tortoise Sustainable and Social Impact Term Fund (NYSE:TEAF)

OVERLAND PARK, KS / ACCESSWIRE / November 4, 2024 / Tortoise Capital announced distributions declared by its closed-end funds.

Tortoise Capital closed-end funds distribution details are as follows:

Fund

Ticker

Distribution
Amount

Distribution Target of Average NAV

Distribution

Frequency

Tortoise Energy Infrastructure Corp.

TYG

$0.78

7%-10%

Quarterly

Tortoise Midstream Energy Fund, Inc.

NTG

$0.81

7%-10%

Quarterly

Tortoise Pipeline & Energy Fund, Inc.

TTP

$0.59

7%-10%

Quarterly

Tortoise Energy Independence Fund, Inc.

NDP

$0.63

7%-10%

Quarterly

Tortoise Power and Energy Infrastructure Fund, Inc.

TPZ

$0.105

7%-10%

Monthly

Tortoise Sustainable and Social Impact Term Fund

TEAF

$0.09

6%-8%

Monthly

TYG, NTG, TTP, NDP and TPZ distributions are payable on Nov. 29, 2024, to shareholders of record on Nov. 22, 2024. TEAF monthly distributions are payable on December 31, 2024, January 31, 2025, and February 28, 2025, to shareholders of record on the respective dates of December 24, 2024, January 24, 2025, and February 21, 2025.

For book purposes, the source of distributions for TYG is estimated to be 10-20% ordinary income and NTG is estimated to be 0-20% ordinary income with the remainder as return of capital, and NDP is estimated to be approximately 10-20% ordinary income, with the remainder as return of capital. For TEAF, the source of distributions is estimated to be approximately 40 to 50% ordinary income, with the remainder as return of capital.

Investors should not draw any conclusions about TTP's or TPZ's investment performance from the amount of these distributions or from the terms of TTP's or TPZ's distribution policy.

TTP and TPZ estimate that they have distributed more than their income and net realized capital gains; therefore, a portion of the distribution may be return of capital. A return of capital may occur, for example, when some or all of the money invested in TTP and TPZ is paid back to the investor. A return of capital distribution does not necessarily reflect TTP's and TPZ's investment performance and should not be confused with "yield" or "income."

TTP and TPZ will report the sources for their distributions at the time of the payment in the applicable Section 19(a) Notice. The amounts and sources of distributions TTP and TPZ report are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon TTP's and TPZ's investment experience during the remainder of their fiscal years and may be subject to changes based on tax regulations.

About Tortoise Capital

With approximately $8.6 billion in assets under management as of September 30, 2024, Tortoise Capital's solid record of investment experience and research dates back more than 20 years. As one of the earliest investors in midstream energy, Tortoise Capital believes it is well-positioned to be at the forefront of the global energy evolution that is under way. Based in Overland Park, Kansas, Tortoise Capital Advisors, L.L.C. is an SEC-registered fund manager that invests primarily in publicly traded companies in the energy and power infrastructure sectors-from production to transportation to distribution. For more information about Tortoise Capital, visit www.TortoiseAdvisors.com.

Tortoise Capital Advisors, L.L.C. is the adviser to Tortoise Energy Infrastructure Corp., Tortoise Midstream Energy Fund, Inc., Tortoise Pipeline & Energy Fund, Inc., Tortoise Energy Independence Fund, Inc., Tortoise Power and Energy Infrastructure Fund, Inc. and Tortoise Sustainable and Social Impact Term Fund.

For additional information on these funds, please visit cef.tortoiseadvisors.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included herein are "forward-looking statements." Although the funds and Tortoise Capital Advisors believe that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the fund's reports that are filed with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required by law, the funds and Tortoise Capital Advisors do not assume a duty to update this forward-looking statement.

Media Contacts

Margaret Kirch Cohen/Richard Chimberg
Newton Park PR
+1 847-507-2229
+1 617-312-4281
margaret@newtonparkpr.com
rich@newtonparkpr.com

SOURCE: Tortoise Capital



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.